Presentation
Many CBI projects are developed in partnership with industrial players. Our scientific advances are assessed in terms of patentability, potential therapeutic applications and industrial or commercial exploitation.
Jérôme Castandet, our Business Developer is involved in developing industrial partnerships, through service provision, research collaborations and Laboratoires Communs (LabCom). These activities are carried out in close collaboration with Partnerships and Valorisation Department (SPV) of the CNRS Occitanie Ouest Regional Delegation (DR14), CNRS Innovation, the CNRS Technology Transfer Office, Toulouse Tech Transfer (TTT), la Société d’Accélération du Transfert de Technologies (SATT) of Toulouse and the CNRS Ingénieurs Transfert national program.
In 2024, the CNRS LabCom Trans NMDA was established between Rest Therapeutics and three CNRS laboratories – CBI-CRCA (for in vivo biology), IPBS (for in vitro biology) and LHFA (for chemistry) – to develop translational research programs targeting the NMDA glutamate receptor family.
CBI has built numerous research collaborations and service agreements with industrial partners such as Enterosys, Eurofins Calixar, Gataca Systems, Humana Biosciences, Inscoper, Koppert, LabSoft, Mibelle Group Biochemistry, NeoVirTech, Oxxius, Phodé, Pierre Fabre and ReST Therapeutics.
Through the Business Developer, CBI works closely with CNRS Innovation and Toulouse Tech Transfer (TTT), focused on accelerating innovation through technology transfer and the creation of start-ups, in order to:
– Identify projects and results from laboratories with high potential of valorization
– Invest in inventions with significant societal impact, providing support for proof-of-concept and prototype development to attract industrial interest
– Protect innovations through patent filing
Since 2021, two TTT pre-maturation grants have been awarded to the laboratory (Drs. S. Lebaron et T. Mangeat).
One patent (Dr. T. Mangeat) based on RIM technology developed at the CBI has been filed.
In 2024, two invention disclosure statements from projects developed at the CBI have been filed with TTT and are currently under evaluation (Drs. F. Escaffit et M. Carraz in collaboration with Institut de Recherche pour le Développement : IRD).
TTT also facilitates the transfer of these inventions to companies through licensing and supports start-up creation.
In 2014, the NeoVirTech company was created on the basis of research carried out in Dr. K. Bystricky’s team at CBI-MCD.
Resulting from CBI research and work carried out on the LITC microscopy platform, the RIMEO start-up creation project which makes it possible to obtain high-resolution images with low-resolution microscopes is currently in progress by Dr. S. Labouesse.
Each year, CBI supports several doctoral students through the CIFRE program (Convention Industrielle de Formation par la Recherche). This program fosters public-private research partnerships by co-financing the training of doctoral students hired by a company. The research mission assigned to these students aligns with the company’s R&D strategy and is conducted in collaboration with an academic laboratory. In 2024, three CIFRE thesis are in progress at the laboratory (directed by Dr. M. Chavent with Eurofins Calixar, Dr. B. Guiard with Phodé and Dr. C. Pasquaretta with Colomiers Rugby).
CBI has built numerous research collaborations, service provisions and Laboratoire Commun (LabCom) with industrial partners such as Enterosys, Eurofins Calixar, Gataca Systems, Humana Biosciences, Inscoper, Koppert, LabSoft, Mibelle Group Biochemistry, NeoVirTech, Oxxius, Phodé, Pierre Fabre and ReST Therapeutics.
